Search MapQuest

Azurity Pharmaceuticals, Inc

841 Woburn St

Wilmington, MA 01887

CutisPharma is a pharmaceutical company based in Wilmington, MA, specializing in the development and manufacturing of innovative drug formulations.

With a focus on providing solutions for patients and healthcare professionals, CutisPharma aims to improve medication delivery and efficacy through its unique products and services.

Generated from their business information

Also at this address

Consolidated Marketing Service Inc

Mathmarketing

CMS Associates

Own this business?

Claim it

See a problem?

You might also like

Sizes, Drugs acting on the respiratory system, Business services, nec, nec

Relay Therapeutics

AVI BioPharma is a biopharmaceutical company that develops drugs to treat life-threatening diseases using its patented third generation antisense technology. It has completed clinical trials with its NeuGene antisense drugs in more than 300 subjects, addressing cardiovascular restenosis, infectious diseases, cancer, polycystic kidney disease and drug metabolism. Its most advanced cardiovascular program is for restenosis, where it has completed Phase II trials, evaluating its drug, Resten-NG. AVI BioPharma is also in a Phase II clinical trial with a drug for Hepatitis C infection and its influenza A drug candidate has been confirmed to have efficacy against avian influenza H5N1 in preclinical studies. AVI BioPharma maintains a location in Portland, Ore.

Services, nec, nec, Drugs acting on the respiratory system, Drugs and drug proprietaries

Wyzer Biosciences

Wyzer Biosciences is a cutting-edge biotechnology company based in Cambridge, MA, specializing in innovative research and development within the life sciences industry. With a focus on advancing technologies and solutions in the field of biosciences, Wyzer Biosciences is dedicated to pushing the boundaries of scientific discovery and driving progress in healthcare and beyond. Generated from their business information

Drugs acting on the respiratory system, Drugs and drug proprietaries, Testing laboratories

Alexion Pharmaceuticals, Inc

Alexion Pharmaceuticals is engaged in the discovery and development of therapeutic products aimed at treating patients with an array of diseases, including hematologic and cardiovascular disorders, autoimmune diseases and cancer. Alexion's two primary product candidates, pexelizumab and eculizumab, are currently undergoing evaluation in several clinical development programs with the Federal Drug Administration. Alexion is engaged in discovering and developing a pipeline of additional antibody therapeutics targeting severe unmet medical needs, through its wholly owned subsidiary, Alexion Antibody Technologies. During the fiscal year ended July 31, 2005, eculizumab was in Phase III clinical development for treatment of paroxysmal nocturnal hemoglobinuria , a chronic hematologic disease, and pexelizumab was in clinical development for two acute cardiac indications. Alexion is also pursuing additional potential indications for eculizumab and has other product candidates in earlier stages of development. Alexion Pharmaceuticals is based in Cheshire, Conn.

United States›Massachusetts›Wilmington›Azurity Pharmaceuticals, Inc

Get directions
MapQuest Travel
Route Planner
Print your map
Get help
Search the web
Send feedback

Learn more about our mobile apps.

Enterprise solutions
Claim your business
Developer resources

Jobs
Advertise with us

Terms of use
Privacy policy
Data and licenses
About our ads
Do not sell